be optionally substituted by a group C_1-C_6 alkyl, halo or –OH.

10. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims 1 to 9, together with one or more pharmaceutically acceptable carriers.

11. A compound as claimed in any of claims 1 to 9 for use in the treatment of diseases or conditions which benefit from inhibition of p38 MAP kinase activity.

12. Compounds according to anyone of claims 1 to 9 for use in the treatment of diseases or conditions which benefit from inhibition of p38 MAP kinase activity according to claim 11 wherein the diseases or conditions is chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy or airways disease that is associated with pulmonary hypertension.

~~13. A method of treating diseases or conditions in a human subject which benefit from inhibition of p38 MAP kinase activity comprising administering to such subject in need thereof a compound as claimed in any of claims 1 to 9.~~

~~14. A method according to claim 13, wherein the disease or condition is chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy or airways disease that is associated with pulmonary hypertension.~~

13~~15~~. The use of a compound as claimed in any of claims 1 to 9 in the manufacture of a medicament for the treatment of diseases or conditions which benefit from inhibition of p38 MAP kinase activity.

14~~16~~. The use according to claim 13~~15~~ wherein the disease or condition is chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome

(ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy or airways disease that is associated with pulmonary hypertension.